Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (Q38989105)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial |
scientific article |
Statements
1 reference
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial (English)
1 reference
1 reference
Robert Landewé
1 reference
Arthur Kavanaugh
1 reference
Iain B McInnes
1 reference
Philip J Mease
1 reference
Bruce Kirkham
1 reference
Christopher T Ritchlin
1 reference
Proton Rahman
1 reference
Alice B Gottlieb
1 reference
Hanno Richards
1 reference
Luminita Pricop
1 reference
Gregory Ligozio
1 reference
Manmath Patekar
1 reference
Shephard Mpofu
1 reference
FUTURE 2 Study Group
1 reference
26 June 2015
1 reference
1 reference
386
1 reference
9999
1 reference
1137-1146
1 reference
Identifiers
1 reference
1 reference